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Aims Iron deficiency is common in patients with heart failure and associated with a poor cardiac function and higher
mortality. How iron deficiency impairs cardiac function on a cellular level in the human setting is unknown. This study
aims to determine the direct effects of iron deficiency and iron repletion on human cardiomyocytes.
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Methods
and results
Human embryonic stem cell-derived cardiomyocytes were depleted of iron by incubation with the iron chelator
deferoxamine (DFO). Mitochondrial respiration was determined by Seahorse Mito Stress test, and contractility was
directly quantified using video analyses according to the BASiC method. The activity of the mitochondrial respiratory
chain complexes was examined using spectrophotometric enzyme assays. Four days of iron depletion resulted in
an 84% decrease in ferritin (P < 0.0001) and significantly increased gene expression of transferrin receptor 1 and
divalent metal transporter 1 (both P < 0.001). Mitochondrial function was reduced in iron-deficient cardiomyocytes,
in particular ATP-linked respiration and respiratory reserve were impaired (both P < 0.0001). Iron depletion affected
mitochondrial function through reduced activity of the iron–sulfur cluster containing complexes I, II and III, but not
complexes IV and V. Iron deficiency reduced cellular ATP levels by 74% (P < 0.0001) and reduced contractile force by
43% (P < 0.05). The maximum velocities during both systole and diastole were reduced by 64% and 85%, respectively
(both P < 0.001). Supplementation of transferrin-bound iron recovered functional and morphological abnormalities
within 3 days.
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Conclusion Iron deficiency directly affects human cardiomyocyte function, impairing mitochondrial respiration, and reducing
contractility and relaxation. Restoration of intracellular iron levels can reverse these effects.
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Introduction
Iron deficiency is a highly clinical relevant co-morbidity, present in
40% of patients with chronic heart failure, even in non-anaemic
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.. patients,1–4 and is related to impaired exercise capacity, reduced
quality of life and a worse prognosis.5–8
In addition to its key role in oxygen uptake and transport as a
part of haemoglobin, iron has an important role in cellular oxygen
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storage and metabolism, redox cycling and as an enzymatic cofac-
tor. Therefore, maintaining a normal iron homeostasis is crucial for
cells that have a high energy demand such as cardiomyocytes.
Iron deficiency impairs functional status in heart failure patients
independently of haemoglobin levels.9 In line with this, treatment
with intravenous iron improves exercise capacity and symptoms
in heart failure patients with iron deficiency, also when they are
non-anaemic.10,11 Data from two small clinical studies in patients
with heart failure and renal failure showed that intravenous iron
improved left ventricular ejection fraction.12,13 Also, data from
several animal studies demonstrated that cardiac iron deficiency
induced by cardiomyocyte specific deletion of the transferrin
receptor (TfRC) hepcidin (HAMP), or iron-regulatory proteins
leads to impaired cardiac function and increased mortality.14–17
These effects are independent of systemic haemoglobin levels.
No studies have assessed the consequences of iron deficiency
in human cardiomyocytes. We determined the effects of iron
deficiency on human embryonic stem (hES) cell-derived car-
diomyocytes. Since mitochondria are the key sites of cellular iron
utilization and ATP production, we focused on mitochondrial
function and contractility. Subsequently, we assessed whether iron




HUES9 hES cells (Harvard Stem Cell Institute) were maintained in
Essential 8 medium (A1517001; Thermo Fisher Scientific, Waltham,
MA, USA) on a Geltrex-coated surface (A1413301; Thermo Fisher
Scientific); medium was refreshed daily. Cells were incubated under
controlled conditions with 37 ∘C, 5% CO2 and 100% atmospheric
humidity. Differentiation to cardiomyocytes was achieved as described
previously.18 Briefly, hES cells were dissociated with 1x TrypLE
(12604-021; Thermo Fisher Scientific) for 4min and plated as single
cells in Essential 8 medium containing 5𝜇M Y26732 (S1049, Selleck
Chemicals, Houston, TX, USA); Essential 8 medium (without Y26732)
was refreshed daily. Once cultures reached 80% confluency, cells were
washed with phosphate buffered saline (PBS) and differentiation was
initiated (day 0) by culturing cells in RPMI1640 medium (21875-034,
Thermo Fisher Scientific) supplemented with 1x B27 minus insulin
(Thermo Fisher Scientific) and 6𝜇M CHIR99021 (13122, Cayman
Chemical, Ann Arbor, MI, USA). At day 2, cells were washed with
PBS and medium was refreshed with RPMI1640 supplemented with
1x B27 minus insulin and 2𝜇M Wnt-C59 (5148, Tocris Bioscience,
Bristol, UK). From day 4, medium was changed to CDM3 medium as
described by Burridge et al.19 and was refreshed every other day as
cardiomyocyte maintenance medium. This resulted in cultures with
>90% spontaneously contracting cardiomyocytes at day 8–10. To
further enrich these cultures, starting from day 12, differentiated car-
diomyocytes were cultured in glucose-free RPMI1640-based (11879,
Thermo Fisher Scientific) CDM3 medium supplemented with 5mM
sodium DL-lactate (CDM3L; L4263, Sigma-Aldrich, St Louis, MO, USA)
for 6–10 days.19 This resulted in >99% pure spontaneously beating



















































































.. Iron chelation and restitution
In order to deplete the intracellular iron pool, cells were treated with
30𝜇M deferoxamine (DFO; D9533, Sigma-Aldrich) in CDM3 medium,
which was added to cells at 0.1mL/cm2.20 To restore intracellular iron
levels, cells were incubated with CDM3 medium supplemented with
5𝜇g/mL partially saturated transferrin (T8158, Sigma-Aldrich). During
experiments, medium was refreshed daily for all conditions.
Statistical analysis
Experimental groups consisted of at least three biological replicates
and technical duplicates were used. Data shown are representative
for three independent experiments and are expressed as means ±
standard error of the mean. Differences between two groups were
assessed by Student’s t-test, while comparisons between three or more
groups were assessed by one-way ANOVA followed by Bonferroni
post-hoc test. Kruskal–Wallis test was used to compare the difference
between groups with non-parametric variances followed by Dunn’s
post-hoc test. A P-value of <0.05 was considered statistically signifi-
cant.
For remaining methods, see supplementary material online,Methods
S1 and Table S1.
Results
Induction of iron deficiency in stem
cell-derived cardiomyocytes
To characterize the generated human cardiomyocytes, cells were
stained for cardiac markers and cardiac-specific gene expression
was determined. Differentiated cardiomyocytes stained positive for
𝛼-actinin and cardiac troponin T, showing a clear cross-striation
pattern that is a hallmark of cardiomyocytes (online supplementary
Figure S1A). Cardiac genes were found to be activated exclusively in
differentiated cardiomyocytes whereas expression of pluripotency
genes was exclusively found in hES cells (online supplementary
Figure S1B). The observation that these cardiomyocytes show
spontaneous contraction verifies stem cell differentiation towards
cardiomyocytes.
To determine iron levels, intracellular ferritin levels were used as
a proxy for cellular iron status. Incubating cardiomyocytes with the
iron chelator DFO for 4 days resulted in 84% reduction in ferritin
levels (P < 0.0001; Figure 1A). Iron depletion for more than 4 days
resulted in cell death.
Gene expression analysis showed that expression levels of genes
involved in iron uptake [TfRC, solute carrier family 11 member 2
(SLC11A2) and solute carrier family 39 member 14 (SLC39A14)]
significantly increased in concert with a decrease of ferritin lev-
els (Figure 1B). Additionally, iron depletion was associated with
increased gene expression levels of ferritin heavy chain 1 (FTH1),
ferritin light chain (FTL), 5’-aminolevulinate synthase 1 (ALAS1) and
heme oxygenase 2 (HMOX2) (online supplementary Figure S2). Fur-
thermore, iron deficiency resulted in increased protein levels of
hypoxia-inducible factor 1 alpha (HIF1𝛼), indicating a hypoxic cel-
lular response (Figure 1C).
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 In vitro iron deficiency is obtained through deferoxamine (DFO) incubation. Ferritin levels decrease in a time-dependent fashion
during DFO incubation (A). Low iron levels lead to induced gene transcription levels of genes involved in iron uptake, transport, and storage
(B). (C) Hypoxia-inducible factor 1 alpha (HIF1𝛼) protein levels in relation with 𝛼-tubulin levels during DFO incubation. N.D., not determined;
SLC11A2, solute carrier family 11 member 2; SLC39A14, solute carrier family 39 member 14; TfRC, transferrin receptor. **P < 0.01;
***P < 0.001; ****P < 0.0001.
Iron deficiency leads to mitochondrial
dysfunction
To determine global mitochondrial function, first total cellular
ATP levels were measured. ATP levels decreased gradually with
the duration of DFO incubation (Figure 2A). After 2 days of iron
depletion ATP levels were reduced by 46% and after 4 days by
74% (both P < 0.001). To assess which specific elements of the
electron transport chain were affected by iron deficiency, iron
depleted cardiomyocytes were analysed with a Seahorse Mito
Stress test (Figure 2B). Cardiomyocytes treated with DFO for
2 and 4 days showed reduced basal respiration [41% (P < 0.01)
and 79% (P < 0.0001) reduction compared to untreated car-
diomyocytes, respectively]. Injection of oligomycin inhibited ATP
synthase-linked respiration, which was 73% in control cardiomy-
ocytes and 63% (P = 0.098) in cardiomyocytes treated for 2 days
with DFO, while cardiomyocytes treated for 4 days exhibited an
ATP-linked respiration of 30% (P< 0.0001 compared to control,
Figure 2C). Subsequent addition of the uncoupler carbonyl cyanide
p-tri-fluoromethoxy-phenyl-hydrazone (FCCP) induced mitochon-
dria to function at maximum capacity. Figure 2C demonstrates
that only control cardiomyocytes were able to increase the oxy-
gen consumption rate (OCR) above baseline values, indicating a
respiratory reserve. All cardiomyocytes treated with DFO lacked
this reserve regardless of the severity of iron depletion. To deter-
mine whether mitochondrial dysfunction could lead to further
metabolic imbalance, the expression of key genes involved in
(anaerobic) glycolysis or fatty acid metabolism was determined
(online supplementary Figure S3). Iron-deficient cardiomyocytes
showed decreased expression of acetyl-CoA carboxylase 1 and 2
(ACACA and ACACB, respectively) and ATP citrate lyase (ACLY),
while glycolysis genes pyruvate kinase (PKM), hexokinase II (HK2)
and lactate dehydrogenase A (LDHA), but not glucose transporter
4 (GLUT4) were upregulated during iron deficiency. Addition-



















































.. further indicated the metabolic switch from fatty acids to glycolysis
as a response to increased HIF1𝛼 activity. Increased levels of LDHA
is indicative of anaerobic glycolysis. Lipids were stained with Nile
Red in iron-deficient cardiomyocytes (online supplementary Figure
S4A). Indeed, iron deficiency resulted in lipid droplet formation,
which was also confirmed by electron microscopy (online sup-
plementary Figure S4B). To study mitochondrial function in more
detail, the activity of complexes I–V was determined individually.
During iron deficiency, complexes I and II showed the first signs
of aberrant function after 2 days of DFO treatment; 4 days of DFO
treatment also significantly reduced complex III activity levels. No
changes were observed in complexes IV and V.
Transferrin-bound iron rescues
iron-deficient cardiomyocytes
To rescue iron-deficient cardiomyocytes, physiological
transferrin-bound iron was added after 4 days of DFO treat-
ment. We found that transferrin-bound iron was able to restore
ferritin to baseline levels after 2 days of supplementation (Figure
3A). After iron restitution, expression levels of genes involved
in iron uptake (TfRC, SLC11A2 and SLC39A14) were significantly
lower compared to iron-deficient cardiomyocytes, albeit higher
than in control cardiomyocytes (Figure 3B). Expression levels of
FTH1, FTL, ALAS1 and HMOX2 remained significantly increased
compared to untreated controls (online supplementary Figure S5).
Analysis of cellular respiration demonstrated that transferrin-
bound iron treatment resulted in improved mitochondrial function
compared to DFO treatment (Figure 3C). Transferrin-treated
cardiomyocytes showed improved basal respiration. In addi-
tion, ATP-linked respiration was restored after addition of
transferrin-bound iron to DFO-treated cardiomyocytes (Figure
3D, left panel). Furthermore, transferrin-treated cardiomyocytes
had regained a respiratory reserve, reaching 262.1% of baseline
OCR, whereas OCR in iron-deficient cardiomyocytes was not
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 The effect of iron deficiency on mitochondrial function. Decreasing levels of intracellular iron correlate with ATP levels (A).
Representative traces for control cardiomyocytes and cardiomyocytes treated with deferoxamine (DFO) for 2 and 4 days in a Mito Stress test
(B). Effects of iron deficiency on ATP-linked respiration and respiratory reserve are shown in (C). The enzymatic activity of each individual
mitochondrial complex was analysed (D). OCR, oxygen consumption rate. **P < 0.01; ***P < 0.001; ****P < 0.0001.
increased further by the injection of FCCP (Figure 3D, right panel).
Furthermore, addition of transferrin-bound iron to iron-deficient
cardiomyocytes eliminated HIF1𝛼 protein levels in iron-deficient
cardiomyocytes (Figure 3E), and fully restored ATP levels
(Figure 3F).
Additionally, to ascertain whether the observed mitochon-
drial dysfunction was the result of altered localization or a
reduced number of mitochondria, cardiomyocytes were stained
for the mitochondrial membrane marker translocase of outer
mitochondrial membrane 20 (TOM20) and TOM20 protein levels
were determined by western blot. Mitochondrial localization was
found to be aberrant in iron-deficient cardiomyocytes, as opposed
to the perinuclear localization in control cardiomyocytes. TOM20
protein levels did not differ significantly between control cardiomy-





















.. Figure S6). Furthermore, mitochondria of iron-deficient cardiomy-
ocytes were typically found to be swollen and contained electron
dense inclusions (Figure 4A). To determine which chemical elements
were most abundant in these inclusion bodies, energy dispersive
X-ray (EDX) analysis was performed (Figure 4B). Interestingly, the
observed electron dense inclusion bodies contained low amounts
of phosphorus as opposed to high levels of nitrogen and sulfur,
suggesting that protein with a high sulfur content aggregated in
iron-deficient mitochondria.
Contractile function is impaired
in iron-deficient cardiomyocytes
Iron deficiency resulted in a 2.1% fractional area change (FAC) com-
pared to 3.5% FAC of control cardiomyocytes (P < 0.05), while
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Impaired contractility in iron-deficient cardiomyocytes 5
A     B
C     D
Ferritin
Time (days)


















































Oligo FCCP      AntA/Rot
0
Time (min)












































































E     F
α-tubulin
HIF1α

























Figure 3 Effects of iron depletion are reversible by transferrin (Tf) administration. Following Tf-bound iron supplementation, levels of
ferritin (A), gene expression (B), mitochondrial respiration (C), of which ATP-linked respiration and respiratory reserve shown in detail (D),
hypoxia-inducible factor 1 alpha (HIF1𝛼) protein (E), and ATP (F) were mostly found to be restored. AntA, antimycin A; FCCP, carbonyl
cyanide p-tri-fluoromethoxy-phenyl-hydrazone; OCR, oxygen consumption rate; Oligo, oligomycin; Rot, rotenone. *P < 0.05; ***P < 0.001;
****P < 0.0001.
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Mitochondrial morphology is also affected by iron deficiency. Mitochondria in iron-deficient cardiomyocytes appear swollen and
contain electron dense inclusion bodies (A), which were found to contain nitrogen and sulfur based on energy dispersive X-ray (EDX) analysis
(B). Scale bar=1𝜇m. DFO, deferoxamine.
the subsequent addition of transferrin-bound iron could reverse
the FAC to 4.46% (P = 0.19 vs. control; Figure 5, and in more
detail in online supplementary Figure S7 and video S1 and S2).
Systolic maximum velocity (Vmax) was significantly reduced to
0.33% FAC per 20ms under iron-deficient conditions compared
to 0.91% FAC per 20ms (P < 0.001), which was reversible by
addition of transferrin-bound iron to 0.97% FAC per 20ms. Car-
diomyocyte relaxation (diastolic Vmax) was significantly reduced to
0.11% FAC per 20ms in iron-deficient cardiomyocytes, compared















. of transferrin-bound iron to 0.40% FAC per 20ms (P < 0.01), but
remained impaired compared to control (P < 0.05).
The endoplasmic reticulum forms
vacuole-like structures during iron
deficiency
During iron chelation, cardiomyocyte morphology changed
dramatically (online supplementary Figure S8). Vacuoles became
apparent after 3 days of DFO incubation, while most prominent
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 5 Low iron levels resulted in reduced contractile force and impaired systolic and diastolic velocity. The fractional area change (FAC)
of a single contraction for each condition (A) show that iron deficiency impairs contractile force (B). FAC, and maximum systolic and diastolic
velocities (Vmax) are affected by low iron levels, but are restored upon addition of transferrin (Tf)-bound iron. *P < 0.05; **P < 0.01; ***P < 0.001.
DFO, deferoxamine.
after 4 days of DFO incubation. To identify the subcellular
structures from which these vacuoles originated, control car-
diomyocytes and cardiomyocytes after 4 days of DFO incubation
were examined at electron microscopy level (Figure 6 and online
supplementary Figure S9). Both conditions showed physiological
mitochondrial structures as well as defined sarcomeric structures.
Additionally, both conditions showed vast amounts of glycogen in
the cytosol. Iron-deficient cardiomyocytes contained vacuoles with
clear contents. Based on electron microscopy analysis, increased
autophagy or lysosomal activity could be excluded as causes for
vacuoles at this scale. One striking observation was the recurring
formation of large perinuclear vacuoles, which suggested that the
endoplasmic reticulum (ER) was severely affected. To determine
to what extent ER stress plays a role in vacuole formation, an
ER-linked FLIPPER probe was expressed in cardiomyocytes. Vac-
uoles were GFP-positive, demonstrating ER morphology (online

























. ER stress-related genes further indicated that iron-deficient
cardiomyocytes had increased levels of ER stress (online supple-
mentary Figure S10). After the addition of transferrin-bound iron,
the vacuoles disappeared, restoring morphology as observed with
electron and light microscopy (Figure 6 and online supplementary
Figure S11; full data via: http://www.nanotomy.org/PW/temp07/
index.html).
Discussion
Independent of its effects on haemoglobin, iron deficiency neg-
atively impacts exercise capacity, symptoms and prognosis of
patients with heart failure.1,5–8 We therefore hypothesized that
low levels of intracellular iron result in impaired function of
cardiomyocytes, possibly due to compromised mitochondrial res-
piration. In the present study, we demonstrate that iron deficiency
in human cardiomyocytes provokes a hypoxic response and results
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.













Figure 6 Reversible morphological aberrations during iron
deficiency. Electron micrographs of (A) control, (B) iron-deficient,
and (C) transferrin-treated cardiomyocytes. N, nucleus; G, glyco-
gen; V, vacuole. Scale bar= 2𝜇m.
in mitochondrial dysfunction, low levels of ATP and impaired con-
tractility and relaxation. After restoring iron levels, these effects
are reversible. Using an in vitro model with cultured human stem
cell-derived cardiomyocytes, we provide insights into the cellular
effects of iron deficiency.
This study utilizes the iron chelator DFO to induce cellular iron
deficiency. DFO is one of the most used iron-chelating agents
approved for clinical use.21 In vivo, it chelates excess iron by
binding free iron in the bloodstream, whereas it is taken up by
cardiomyocytes via endocytosis in vitro.22 Once internalized, DFO
efficiently chelates iron and subsequently depletes the cellular iron
pool (i.e. ferritin-bound iron). In our experiments, medium was
refreshed daily to prevent DFO from reaching an equilibrium with



















































































.. to DFO, we tested multiple other iron-chelating agents, including
deferasirox, deferiprone, dexrazoxan, PIH, bipyridyl. However, in
our experiments, DFO was found to be most effective. In response
to iron depletion, cardiomyocytes induce a gene expression pattern
that greatly promotes iron uptake and transport. The obtained
model of iron deficiency may be more severe than what can
be expected in iron-deficient patients and may therefore not be
directly translatable to the in vivo pathophysiology. However, direct
comparison is difficult as circulating ferritin levels are assessed in
patients while we measured cellular ferritin levels. The cellular and
circulation systems might be subjected to separate and different
regulatory mechanisms.
Low iron levels resulted in significantly reduced levels of ATP,
which suggests mitochondrial dysfunction. The remaining levels of
ATP are mainly produced by other mechanisms, such as anaerobic
glycolysis and phosphocreatine conversion. We have shown that
iron-deficient cardiomyocytes undergo a metabolic switch from
fatty acid oxidation to anaerobic glycolysis. However, we have not
determined a possible imbalance between the respiratory chain and
the citric acid cycle. In conditions with a sufficient environmental
partial oxygen tension, iron-deficient cardiomyocytes are unable to
transport and utilize sufficient amounts or oxygen. In itself, reduced
oxygen transport may account for mitochondrial dysfunction by
inhibition of complex IV, whereas oxidative phosphorylation in gen-
eral is hampered by aberrant redox cycling as a result of iron defi-
ciency. Interestingly, only the activity of mitochondrial complexes
I–III, which all contain iron–sulfur (Fe-S) clusters, were affected by
DFO treatment, while the activity of the exclusively heme-based
complexes IV and V remained unaltered. This observation confirms
data of a previous study reporting low levels of cytosolic non-heme
iron and increased levels of cytosolic and mitochondrial heme in
cardiac tissue of patients with advanced heart failure.23 Addition-
ally, these data are in line with those from Rensvold et al.24 that
showed comparable mitochondrial function under iron-deficient
conditions. Moreover, Rensvold et al. observed decreased levels
of complexes I, II and IV following 24 h of 100𝜇M DFO incuba-
tion, whereas we demonstrate that complexes I–III show a reduced
enzymatic activity after DFO incubation. Reduced protein levels of
these complexes may support our observation of reduced com-
plex activity. Finally, Melenovsky et al.25 also showed a decreased
activity of mitochondrial complex I and III in heart failure patients.
Gene expression levels of the genes encoding ALAS1 and HMOX2
are both increased during iron deficiency. These genes encode
for proteins with antagonistic functions; the underlying regulatory
mechanism with regard to heme conservation remains unclear.
After restoring the ferritin levels with supplemented
transferrin-bound iron, the effects of iron deficiency on the
cardiomyocytes regarding iron metabolism, HIF1𝛼 protein levels,
ATP production, and mitochondrial respiration could be mostly
restored. These observations indicate that the cellular effects of
iron deficiency are highly reversible. In clinical trials, it has already
been shown that iron deficiency can be reversed. CONFIRM-HF
and FAIR-HF both show improvements in exercise capacity and
symptoms.26,27 In case of the FAIR-HF, these improvements were
already observed 4weeks after the initial dose of intravenous
iron.27 Interestingly, after iron restitution, genes transcribing
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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ferritin light and heavy chains ALAS1 and HMOX2 remain induced
(online supplementary Figure 5). These genes were found to be
active in other forms of stress as well, indicating that these effects
are not specific for iron deficiency, but rather are induced by
various stress responses (e.g. hypoxic responses, reduced ATP
levels, and ER stress).28–30
Iron-depleted cardiomyocytes generate less force compared
to untreated controls. Impaired contractile function could be
fully restored by the addition of transferrin-bound iron with
regard to FAC and systolic Vmax, while cardiomyocyte relax-
ation only partially restored. These findings suggest that diastolic
function is affected more permanent than systolic force and
velocity. Ultimately, low levels of intracellular iron result in a
diminished diastolic function in vitro, confirming observations from
clinical cases.31
Morphological examination of the iron-depleted cardiomyocytes
revealed swollen mitochondria containing electron dense mate-
rial, as well as vacuole formation. Interestingly, mitochondrial dys-
function is observed in concert with morphological abnormalities.
Previous studies found inclusion bodies in iron-deficient mitochon-
dria, an observation that is strikingly similar to our observations.32
These inclusion bodies were found to be rich in sulfur and nitrogen,
but not phosphorus, excluding the presence of DNA. These find-
ings may indicate that Fe-S cluster remnants form aggregates with
associated proteins. Additionally, the primary source of these vac-
uoles is the ER, as indicated by electron and light microscopy. The
ER plays a major role in stress responses in general, which seems to
be excessive during severe iron deficiency. ER stress-related genes
were found to be induced during iron deficiency, which links iron
deficiency to ER stress.33 Furthermore, we show that lipid handling
and homeostasis are severely disrupted by iron deficiency, which
has been shown previously.34
Our data further emphasize the potential negative effects of
an impaired cardiac iron metabolism on the heart directly and
independently of systemic iron, or heme, levels. Similar results
were reported by in vitro and animal studies for intracellular iron
status in skeletal muscle, showing deranged mitochondrial mor-
phology with an impaired oxidative metabolism, impaired activity
of mitochondrial complexes I and II, decreased Fe-S cluster syn-
thesis and a shift to anaerobic glycolysis.24 These cellular effects
might be relevant when considering that strategies targeting the
hepcidin/ferroportin axis are being developed. These agents lower
hepcidin levels and increase ferroportin [solute carrier family 40
member 1 (SLC40A1)] expression, thereby increasing systemic iron
levels and availability. However, this axis is also present and func-
tional in the heart.15 An increased cardiac SLC40A1 expression
leads to iron export and lower intracellular iron levels in the car-
diomyocyte, which might be counterproductive.9 Importantly, car-
diac HAMP and SLC40A1 expression might be subject to regulation
independent of their systemic counterparts.
In conclusion, cellular iron deficiency results in a reduced activity
of Fe-S cluster-based complexes in the mitochondria of human
cardiomyocytes and is associated with impaired mitochondrial
respiration and morphology, ATP production and contractility.



















































































.. study provides mechanistic insights into how treatment of iron
deficiency may lead to improved cardiac function.
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